Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
daclatasvir (Daklinza®)
Reference No. 1464
Publication date:
20/05/2015
Appraisal information
daclatasvir (Daklinza®) 30 mg film-coated tablet
daclatasvir (Daklinza®) 60 mg film-coated tablet
Company:
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category:
Infections
NMG meeting date:
25/02/2015
AWMSG meeting date:
25/03/2015
Submission Type:
Full Submission
Status:
Superseded
Advice No:
0615
Ratification by Welsh Government:
15/05/2015
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA364) NICE GUIDANCE ISSUED NOVEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). Daclatasvir (Daklinza®) in combination with other medicinal products is recommended as an option for restricted use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in adults. Use should be restricted to patients with significant fibrosis (METAVIR score ≥ F3) or compensated cirrhosis. Daclatasvir (Daklinza®) in combination with other medicinal products is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
daclatasvir (Daklinza) 1464 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
daclatasvir (Daklinza) 1464 ASAR
Clinical Expert (CE) Summary
Download
daclatasvir (Daklinza) 1464 CE Summary